Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Multi-Center Phase II Study of the BRAF Inhibitor RO5185426 in Patients With Metastatic or Unresectable Papillary Thyroid Cancer (PTC) Positive for the BRAF V600 Mutation and Resistant to Radioactive Iodine.

Next Previous
Search
Trial Profile

An Open-Label, Multi-Center Phase II Study of the BRAF Inhibitor RO5185426 in Patients With Metastatic or Unresectable Papillary Thyroid Cancer (PTC) Positive for the BRAF V600 Mutation and Resistant to Radioactive Iodine.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vemurafenib (Primary)
  • Indications Thyroid cancer
  • Focus Therapeutic Use
  • Sponsors Roche

    • Most Recent Events

    • 22 Jul 2016 Study design has been changed from single group assignment to parallel group assignment. Also reatment arms has been changed from 1 to 2.
    • 22 Jul 2016 Status changed from active, no longer recruiting to completed.
    • 07 Apr 2014 Planned End Date changed from 1 May 2015 to 1 Oct 2015 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top